top of page
Fleet's Hampshire laboratories

Sam Scrimshaw


Immunoassay Development Director

Has over 25 years’ experience of the development and validation of immunoassays for a variety of purposes, from forensic testing and bioanalysis, to biomarker, immunogenicity assessment and infectious disease serology. Sam has worked at the Horseracing Forensic Laboratory, GSK, Huntingdon Life Sciences, Abcam and Trinity Biotech, and is experienced in ELISA, RIA, haemagglutination, Biacore SPR, AlphaLISA, lateral flow assays, MSD, polyclonal and monoclonal antibody development and transfer of assays to other laboratory environments including GMP manufacture. Sam also has experience providing testimony as an Expert Witness, including cross-examination at the High Court. Sam joined Fleet in 2015 and was appointed a Director in 2016.


The development of lateral flow immunoassays for equine pre-race testing. S.J. Scrimshaw (2000) Proc. 13th ICRAV, Cambridge, U.K

Development of a rapid lateral flow immunoassay for the detection of the alpha-2 agonist romifidine in equine plasma. S. Scrimshaw, S. Mayoss, J. Fox & J. Roberts (2002) Proc. 14th ICRAV, Florida, USA

The application of a surface plasmon resonance biosensor (Biacore Q system) to drug screening in equine samples. S. Scrimshaw, S. Mayoss, J. Roberts, C. Elliott and S. Biddle (2004) Proc. 15th ICRAV, Dubai, UAE.

Impact of Bioconjugation on Structure and Function of Antibodies for Use in Immunoassay by Hydrogen-Deuterium Exchange Mass Spectrometry. L. Luckau, K. Groves, C. Blencowe, S. Scrimshaw, A. Dent and M. Quaglia (2022) Frontiers in Molecular Biosciences.

Company Management

bottom of page